Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.

NCT Number	NCT02864992
Lead Sponsor	EMD Serono Research & Development Institute, Inc. Collaborators: Merck KGaA, Darmstadt, Germany
Conditions	Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Enrollment	337 participants
Start Date	2016-09-13
Primary Completion	2022-05-16 (estimated)
Study Completion	2026-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-14